Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Conditions
Epidermolysis Bullosa
Interventions
SD-101 dermal cream (6%)
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
6 Months and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
Conditions
Epidermolysis Bullosa, Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Dystrophica
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Conditions
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans
Interventions
Not listed
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Spincare matrix
Device
Lead sponsor
Stanford University
Other
Eligibility
6 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Redwood City, California
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
AGLE-102
Drug
Lead sponsor
Aegle Therapeutics
Industry
Eligibility
6 Months and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Phoenix, Arizona • Los Angeles, California • Philadelphia, Pennsylvania
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Prademagene Zamikeracel
Combination Product
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2045
U.S. locations
4
States / cities
Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 1 more
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
Granulocyte Colony Stimulating Factor (GCSF)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients

NCT03536143
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
Topical beremagene geperpavec, Placebo gel
Biological
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
2 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Stanford, California
Conditions
Epidermolysis Bullosa Dystrophica
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
1
States / cities
Stanford, California
Conditions
Epidermolysis Bullosa
Interventions
Survey
Other
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Cranbury, New Jersey
Completed Phase 1Phase 2 Interventional Results available

Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

NCT01263379
Conditions
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
Interventions
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
13 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Redwood City, California
Conditions
Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica
Interventions
Apligraf, Standard dressing regimen
Device · Other
Lead sponsor
Organogenesis
Industry
Eligibility
2 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Stanford, California • Miami, Florida • New York, New York + 2 more
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
KB803, Placebo
Biological · Drug
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Rancho Santa Margarita, California • Coral Gables, Florida • Worcester, Massachusetts + 2 more
Conditions
Epidermolysis Bullosa Dystrophica, Recessive
Interventions
FCX-007
Genetic
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
7 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Conditions
Epidermolysis Bullosa
Interventions
SD-101-6.0 cream, Placebo (SD-101-0.0) cream
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
1 Month and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
21
States / cities
Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 17 more
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Rigosertib Sodium, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions
Efgartigimod
Biological
Lead sponsor
M. Peter Marinkovich
Other
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Redwood City, California
Conditions
Epidermolysis Bullosa
Interventions
SD-101-6.0 cream
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
1 Month and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 12 more
Recruiting No phase listed Observational

Long-Term Follow-up Protocol

NCT04917887
Conditions
Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
Not listed
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
Interventions
Not listed
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Redwood City, California
Completed Phase 1Phase 2 Interventional Results available

Gentamicin for RDEB

NCT03012191
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Gentamicin Sulfate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
Open Label Topical Beremagene Geperpavec (B-VEC)
Biological
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
2 Months and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida + 3 more
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
D-Fi
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
4
States / cities
Redwood City, California • Santa Margarita, California • Aurora, Colorado + 1 more
Conditions
Epidermolysis Bullosa (EB), Epidermolysis Bullosa Simplex, Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
Interventions
Diacerein 1% Ointment
Drug
Lead sponsor
Castle Creek Pharmaceuticals, LLC
Industry
Eligibility
4 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Palo Alto, California • Chicago, Illinois • Chapel Hill, North Carolina